Drugs / pegylated IFNa2b
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT00593151 Comparator | Jan → Dec 2008 | hepatitis C virus infection | Biolex Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pegylated IFNa2b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00593151 ↗ |
| Modality | Protein / enzyme biologic | “biological, weekly subcutaneous injections for 4-12 weeks, 1.5 mcg/kg” NCT00593151 ↗ |
| Route | Subcutaneous | “weekly subcutaneous injections for 4-12 weeks” NCT00593151 ↗ |